Maseco LLP Sells 2,780 Shares of AbbVie Inc. $ABBV

Maseco LLP trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 33.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 5,511 shares of the company’s stock after selling 2,780 shares during the period. Maseco LLP’s holdings in AbbVie were worth $1,259,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Evolution Wealth Management Inc. bought a new position in AbbVie during the 2nd quarter valued at about $26,000. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter valued at about $26,000. Westend Capital Management LLC bought a new position in AbbVie during the 4th quarter valued at about $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the 3rd quarter valued at about $31,000. Finally, Caitlin John LLC bought a new position in AbbVie during the 3rd quarter valued at about $33,000. 70.23% of the stock is owned by institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie sued the U.S. government seeking a narrower definition of which patients qualify for a federal drug-discount program — a move investors see as an attempt to limit mandated discounts and protect revenue/margins. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Positive Sentiment: New dermatology data for Skyrizi and Rinvoq showcased durability, safety and label expansions that support AbbVie’s immunology growth thesis and revenue visibility. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst and dividend-focused coverage highlights ABBV’s strong cash flow and reliable dividend (Dividend Aristocrat status and recent raises), supporting investor demand for income exposure. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation (AbbVie section)
• Neutral Sentiment: Healthcare sector momentum and “trending” stock mentions (Zacks/coverage pieces) are increasing visibility and trading interest in ABBV, which can amplify moves but are not fundamental catalysts by themselves. AbbVie Inc. (ABBV) Is a Trending Stock
• Neutral Sentiment: Brand/marketing activity — Allergan Aesthetics (BOTOX® Cosmetic) programs and new AMI training center openings — support long-term aesthetics revenue but are incremental near-term. BOTOX® Cosmetic Empowers Women Entrepreneurs
• Negative Sentiment: J&J’s Tremfya reclaimed the top spot in TV drug ad spending from AbbVie, suggesting AbbVie pulled back promotional share — a potential headwind to maintaining market momentum against competitors. J&J’s Tremfya retakes TV drug ad spending crown from AbbVie
• Negative Sentiment: AbbVie placed Humira on the TrumpRx platform at a steep discount — a tactical move to maintain access/share that pressures pricing and could weigh on legacy-revenue mix. AbbVie Puts Humira on TrumpRx at Steep Discount
• Negative Sentiment: Some analysts are flagging valuation and competitive concerns; Cantor Fitzgerald trimmed its price target modestly (still overweight), reflecting mixed views on upside vs. risks. Cantor Fitzgerald price target revision note

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on ABBV. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Evercore cut their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. UBS Group lowered their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $252.65.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $211.74 on Thursday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company has a 50 day moving average of $220.80 and a 200-day moving average of $224.19. The stock has a market cap of $374.40 billion, a price-to-earnings ratio of 89.72, a P/E/G ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the company earned $2.16 EPS. AbbVie’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s payout ratio is currently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.